nodes	percent_of_prediction	percent_of_DWPC	metapath
Cinacalcet—CYP2D6—Vinorelbine—ovarian cancer	0.0967	0.255	CbGbCtD
Cinacalcet—CYP3A4—Topotecan—ovarian cancer	0.0873	0.23	CbGbCtD
Cinacalcet—CYP3A4—Vinorelbine—ovarian cancer	0.0615	0.162	CbGbCtD
Cinacalcet—CYP3A4—Paclitaxel—ovarian cancer	0.0432	0.114	CbGbCtD
Cinacalcet—CYP2D6—Doxorubicin—ovarian cancer	0.0366	0.0964	CbGbCtD
Cinacalcet—CYP3A4—Docetaxel—ovarian cancer	0.0312	0.0822	CbGbCtD
Cinacalcet—CYP3A4—Doxorubicin—ovarian cancer	0.0233	0.0613	CbGbCtD
Cinacalcet—CASR—E-cadherin signaling in keratinocytes—CDH1—ovarian cancer	0.00273	0.0811	CbGpPWpGaD
Cinacalcet—CASR—E-cadherin signaling in keratinocytes—CTNNB1—ovarian cancer	0.00201	0.0598	CbGpPWpGaD
Cinacalcet—CASR—E-cadherin signaling in keratinocytes—EGFR—ovarian cancer	0.00159	0.0474	CbGpPWpGaD
Cinacalcet—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00144	0.00246	CcSEcCtD
Cinacalcet—Hypertension—Vinorelbine—ovarian cancer	0.00143	0.00244	CcSEcCtD
Cinacalcet—Depression—Paclitaxel—ovarian cancer	0.00142	0.00243	CcSEcCtD
Cinacalcet—Paraesthesia—Topotecan—ovarian cancer	0.00142	0.00242	CcSEcCtD
Cinacalcet—Cramp muscle—Docetaxel—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Urticaria—Chlorambucil—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Arthralgia—Vinorelbine—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Myalgia—Vinorelbine—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Chest pain—Vinorelbine—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Dyspnoea—Topotecan—ovarian cancer	0.00141	0.00241	CcSEcCtD
Cinacalcet—Abdominal pain—Chlorambucil—ovarian cancer	0.00141	0.0024	CcSEcCtD
Cinacalcet—Body temperature increased—Chlorambucil—ovarian cancer	0.00141	0.0024	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.0014	0.00239	CcSEcCtD
Cinacalcet—Dyspepsia—Topotecan—ovarian cancer	0.00139	0.00238	CcSEcCtD
Cinacalcet—Paraesthesia—Melphalan—ovarian cancer	0.00139	0.00237	CcSEcCtD
Cinacalcet—CASR—E-cadherin signaling in keratinocytes—PIK3CA—ovarian cancer	0.00138	0.0411	CbGpPWpGaD
Cinacalcet—Dyspnoea—Melphalan—ovarian cancer	0.00138	0.00236	CcSEcCtD
Cinacalcet—Decreased appetite—Topotecan—ovarian cancer	0.00138	0.00235	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00137	0.00233	CcSEcCtD
Cinacalcet—Fatigue—Topotecan—ovarian cancer	0.00137	0.00233	CcSEcCtD
Cinacalcet—Dyspepsia—Melphalan—ovarian cancer	0.00136	0.00233	CcSEcCtD
Cinacalcet—Constipation—Topotecan—ovarian cancer	0.00135	0.00231	CcSEcCtD
Cinacalcet—Decreased appetite—Melphalan—ovarian cancer	0.00135	0.0023	CcSEcCtD
Cinacalcet—Infection—Vinorelbine—ovarian cancer	0.00135	0.00229	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00134	0.00228	CcSEcCtD
Cinacalcet—Fatigue—Melphalan—ovarian cancer	0.00134	0.00228	CcSEcCtD
Cinacalcet—Nervous system disorder—Vinorelbine—ovarian cancer	0.00133	0.00226	CcSEcCtD
Cinacalcet—Skin disorder—Vinorelbine—ovarian cancer	0.00132	0.00224	CcSEcCtD
Cinacalcet—Hypersensitivity—Chlorambucil—ovarian cancer	0.00131	0.00223	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Topotecan—ovarian cancer	0.00129	0.00221	CcSEcCtD
Cinacalcet—Anorexia—Vinorelbine—ovarian cancer	0.00129	0.0022	CcSEcCtD
Cinacalcet—Asthenia—Chlorambucil—ovarian cancer	0.00128	0.00218	CcSEcCtD
Cinacalcet—Hypotension—Vinorelbine—ovarian cancer	0.00127	0.00216	CcSEcCtD
Cinacalcet—Oedema peripheral—Paclitaxel—ovarian cancer	0.00126	0.00215	CcSEcCtD
Cinacalcet—Pruritus—Chlorambucil—ovarian cancer	0.00126	0.00215	CcSEcCtD
Cinacalcet—Urticaria—Topotecan—ovarian cancer	0.00126	0.00214	CcSEcCtD
Cinacalcet—Abdominal pain—Topotecan—ovarian cancer	0.00125	0.00213	CcSEcCtD
Cinacalcet—Body temperature increased—Topotecan—ovarian cancer	0.00125	0.00213	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00123	0.0021	CcSEcCtD
Cinacalcet—Urticaria—Melphalan—ovarian cancer	0.00123	0.0021	CcSEcCtD
Cinacalcet—Diarrhoea—Chlorambucil—ovarian cancer	0.00122	0.00207	CcSEcCtD
Cinacalcet—Paraesthesia—Vinorelbine—ovarian cancer	0.00122	0.00207	CcSEcCtD
Cinacalcet—Dyspnoea—Vinorelbine—ovarian cancer	0.00121	0.00206	CcSEcCtD
Cinacalcet—CYP1A2—Sulindac Metabolic Pathway—CYP1B1—ovarian cancer	0.0012	0.0357	CbGpPWpGaD
Cinacalcet—Decreased appetite—Vinorelbine—ovarian cancer	0.00118	0.00201	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00117	0.00199	CcSEcCtD
Cinacalcet—Fatigue—Vinorelbine—ovarian cancer	0.00117	0.00199	CcSEcCtD
Cinacalcet—Hypersensitivity—Topotecan—ovarian cancer	0.00117	0.00199	CcSEcCtD
Cinacalcet—Constipation—Vinorelbine—ovarian cancer	0.00116	0.00197	CcSEcCtD
Cinacalcet—Immune system disorder—Paclitaxel—ovarian cancer	0.00116	0.00197	CcSEcCtD
Cinacalcet—Arrhythmia—Paclitaxel—ovarian cancer	0.00115	0.00195	CcSEcCtD
Cinacalcet—Hypersensitivity—Melphalan—ovarian cancer	0.00114	0.00195	CcSEcCtD
Cinacalcet—Asthenia—Topotecan—ovarian cancer	0.00114	0.00194	CcSEcCtD
Cinacalcet—Vomiting—Chlorambucil—ovarian cancer	0.00113	0.00193	CcSEcCtD
Cinacalcet—CASR—E-cadherin signaling in keratinocytes—AKT1—ovarian cancer	0.00113	0.0336	CbGpPWpGaD
Cinacalcet—Pruritus—Topotecan—ovarian cancer	0.00112	0.00191	CcSEcCtD
Cinacalcet—Malnutrition—Paclitaxel—ovarian cancer	0.00112	0.0019	CcSEcCtD
Cinacalcet—Asthenia—Melphalan—ovarian cancer	0.00111	0.0019	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00111	0.00189	CcSEcCtD
Cinacalcet—Pruritus—Melphalan—ovarian cancer	0.0011	0.00187	CcSEcCtD
Cinacalcet—Cardiac failure—Epirubicin—ovarian cancer	0.00109	0.00185	CcSEcCtD
Cinacalcet—Diarrhoea—Topotecan—ovarian cancer	0.00108	0.00185	CcSEcCtD
Cinacalcet—Urticaria—Vinorelbine—ovarian cancer	0.00108	0.00183	CcSEcCtD
Cinacalcet—Muscle spasms—Paclitaxel—ovarian cancer	0.00107	0.00183	CcSEcCtD
Cinacalcet—Abdominal pain—Vinorelbine—ovarian cancer	0.00107	0.00183	CcSEcCtD
Cinacalcet—Body temperature increased—Vinorelbine—ovarian cancer	0.00107	0.00183	CcSEcCtD
Cinacalcet—Oedema peripheral—Docetaxel—ovarian cancer	0.00107	0.00183	CcSEcCtD
Cinacalcet—Diarrhoea—Melphalan—ovarian cancer	0.00106	0.00181	CcSEcCtD
Cinacalcet—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.00106	0.00181	CcSEcCtD
Cinacalcet—Pain in extremity—Epirubicin—ovarian cancer	0.00106	0.00181	CcSEcCtD
Cinacalcet—Nausea—Chlorambucil—ovarian cancer	0.00106	0.0018	CcSEcCtD
Cinacalcet—Dizziness—Topotecan—ovarian cancer	0.00105	0.00178	CcSEcCtD
Cinacalcet—Anaemia—Paclitaxel—ovarian cancer	0.00103	0.00176	CcSEcCtD
Cinacalcet—Angioedema—Paclitaxel—ovarian cancer	0.00102	0.00174	CcSEcCtD
Cinacalcet—Vomiting—Topotecan—ovarian cancer	0.00101	0.00172	CcSEcCtD
Cinacalcet—Cardiac failure—Doxorubicin—ovarian cancer	0.001	0.00171	CcSEcCtD
Cinacalcet—Rash—Topotecan—ovarian cancer	0.000998	0.0017	CcSEcCtD
Cinacalcet—Hypersensitivity—Vinorelbine—ovarian cancer	0.000998	0.0017	CcSEcCtD
Cinacalcet—Dermatitis—Topotecan—ovarian cancer	0.000997	0.0017	CcSEcCtD
Cinacalcet—Headache—Topotecan—ovarian cancer	0.000992	0.00169	CcSEcCtD
Cinacalcet—Vomiting—Melphalan—ovarian cancer	0.000986	0.00168	CcSEcCtD
Cinacalcet—Dehydration—Epirubicin—ovarian cancer	0.000986	0.00168	CcSEcCtD
Cinacalcet—Immune system disorder—Docetaxel—ovarian cancer	0.000982	0.00167	CcSEcCtD
Cinacalcet—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000981	0.00167	CcSEcCtD
Cinacalcet—Pain in extremity—Doxorubicin—ovarian cancer	0.000981	0.00167	CcSEcCtD
Cinacalcet—Rash—Melphalan—ovarian cancer	0.000978	0.00167	CcSEcCtD
Cinacalcet—Dermatitis—Melphalan—ovarian cancer	0.000977	0.00166	CcSEcCtD
Cinacalcet—Cough—Paclitaxel—ovarian cancer	0.000974	0.00166	CcSEcCtD
Cinacalcet—Asthenia—Vinorelbine—ovarian cancer	0.000972	0.00166	CcSEcCtD
Cinacalcet—Arrhythmia—Docetaxel—ovarian cancer	0.000971	0.00166	CcSEcCtD
Cinacalcet—Convulsion—Paclitaxel—ovarian cancer	0.000967	0.00165	CcSEcCtD
Cinacalcet—Hypertension—Paclitaxel—ovarian cancer	0.000964	0.00164	CcSEcCtD
Cinacalcet—Pruritus—Vinorelbine—ovarian cancer	0.000958	0.00163	CcSEcCtD
Cinacalcet—Chest pain—Paclitaxel—ovarian cancer	0.00095	0.00162	CcSEcCtD
Cinacalcet—Arthralgia—Paclitaxel—ovarian cancer	0.00095	0.00162	CcSEcCtD
Cinacalcet—Myalgia—Paclitaxel—ovarian cancer	0.00095	0.00162	CcSEcCtD
Cinacalcet—Malnutrition—Docetaxel—ovarian cancer	0.000946	0.00161	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000944	0.00161	CcSEcCtD
Cinacalcet—Nausea—Topotecan—ovarian cancer	0.000941	0.0016	CcSEcCtD
Cinacalcet—Diarrhoea—Vinorelbine—ovarian cancer	0.000927	0.00158	CcSEcCtD
Cinacalcet—Nausea—Melphalan—ovarian cancer	0.000921	0.00157	CcSEcCtD
Cinacalcet—Dehydration—Doxorubicin—ovarian cancer	0.000912	0.00155	CcSEcCtD
Cinacalcet—Muscle spasms—Docetaxel—ovarian cancer	0.00091	0.00155	CcSEcCtD
Cinacalcet—Infection—Paclitaxel—ovarian cancer	0.000905	0.00154	CcSEcCtD
Cinacalcet—Dizziness—Vinorelbine—ovarian cancer	0.000896	0.00153	CcSEcCtD
Cinacalcet—Nervous system disorder—Paclitaxel—ovarian cancer	0.000893	0.00152	CcSEcCtD
Cinacalcet—Skin disorder—Paclitaxel—ovarian cancer	0.000885	0.00151	CcSEcCtD
Cinacalcet—Anaemia—Docetaxel—ovarian cancer	0.000875	0.00149	CcSEcCtD
Cinacalcet—Anorexia—Paclitaxel—ovarian cancer	0.000868	0.00148	CcSEcCtD
Cinacalcet—Vomiting—Vinorelbine—ovarian cancer	0.000861	0.00147	CcSEcCtD
Cinacalcet—Rash—Vinorelbine—ovarian cancer	0.000854	0.00146	CcSEcCtD
Cinacalcet—Dermatitis—Vinorelbine—ovarian cancer	0.000853	0.00145	CcSEcCtD
Cinacalcet—Hypotension—Paclitaxel—ovarian cancer	0.000851	0.00145	CcSEcCtD
Cinacalcet—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000851	0.00145	CcSEcCtD
Cinacalcet—Headache—Vinorelbine—ovarian cancer	0.000849	0.00145	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00083	0.00141	CcSEcCtD
Cinacalcet—Cough—Docetaxel—ovarian cancer	0.000826	0.00141	CcSEcCtD
Cinacalcet—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.000825	0.0245	CbGpPWpGaD
Cinacalcet—Convulsion—Docetaxel—ovarian cancer	0.00082	0.0014	CcSEcCtD
Cinacalcet—Paraesthesia—Paclitaxel—ovarian cancer	0.000818	0.00139	CcSEcCtD
Cinacalcet—Hypertension—Docetaxel—ovarian cancer	0.000817	0.00139	CcSEcCtD
Cinacalcet—Dyspnoea—Paclitaxel—ovarian cancer	0.000812	0.00138	CcSEcCtD
Cinacalcet—Arthralgia—Docetaxel—ovarian cancer	0.000806	0.00137	CcSEcCtD
Cinacalcet—Myalgia—Docetaxel—ovarian cancer	0.000806	0.00137	CcSEcCtD
Cinacalcet—Chest pain—Docetaxel—ovarian cancer	0.000806	0.00137	CcSEcCtD
Cinacalcet—Nausea—Vinorelbine—ovarian cancer	0.000805	0.00137	CcSEcCtD
Cinacalcet—Dyspepsia—Paclitaxel—ovarian cancer	0.000802	0.00137	CcSEcCtD
Cinacalcet—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.000802	0.0238	CbGpPWpGaD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.0008	0.00136	CcSEcCtD
Cinacalcet—Decreased appetite—Paclitaxel—ovarian cancer	0.000792	0.00135	CcSEcCtD
Cinacalcet—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000788	0.00134	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000787	0.00134	CcSEcCtD
Cinacalcet—Fatigue—Paclitaxel—ovarian cancer	0.000786	0.00134	CcSEcCtD
Cinacalcet—Constipation—Paclitaxel—ovarian cancer	0.000779	0.00133	CcSEcCtD
Cinacalcet—Infection—Docetaxel—ovarian cancer	0.000767	0.00131	CcSEcCtD
Cinacalcet—Nervous system disorder—Docetaxel—ovarian cancer	0.000757	0.00129	CcSEcCtD
Cinacalcet—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00075	0.0223	CbGpPWpGaD
Cinacalcet—Skin disorder—Docetaxel—ovarian cancer	0.00075	0.00128	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000745	0.00127	CcSEcCtD
Cinacalcet—Anorexia—Docetaxel—ovarian cancer	0.000736	0.00125	CcSEcCtD
Cinacalcet—Urticaria—Paclitaxel—ovarian cancer	0.000724	0.00123	CcSEcCtD
Cinacalcet—Oedema peripheral—Epirubicin—ovarian cancer	0.000722	0.00123	CcSEcCtD
Cinacalcet—Hypotension—Docetaxel—ovarian cancer	0.000722	0.00123	CcSEcCtD
Cinacalcet—Body temperature increased—Paclitaxel—ovarian cancer	0.00072	0.00123	CcSEcCtD
Cinacalcet—Abdominal pain—Paclitaxel—ovarian cancer	0.00072	0.00123	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000704	0.0012	CcSEcCtD
Cinacalcet—Paraesthesia—Docetaxel—ovarian cancer	0.000693	0.00118	CcSEcCtD
Cinacalcet—Dyspnoea—Docetaxel—ovarian cancer	0.000688	0.00117	CcSEcCtD
Cinacalcet—Dyspepsia—Docetaxel—ovarian cancer	0.00068	0.00116	CcSEcCtD
Cinacalcet—Decreased appetite—Docetaxel—ovarian cancer	0.000671	0.00114	CcSEcCtD
Cinacalcet—Hypersensitivity—Paclitaxel—ovarian cancer	0.000671	0.00114	CcSEcCtD
Cinacalcet—Oedema peripheral—Doxorubicin—ovarian cancer	0.000668	0.00114	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000667	0.00114	CcSEcCtD
Cinacalcet—Fatigue—Docetaxel—ovarian cancer	0.000666	0.00113	CcSEcCtD
Cinacalcet—Immune system disorder—Epirubicin—ovarian cancer	0.000662	0.00113	CcSEcCtD
Cinacalcet—Constipation—Docetaxel—ovarian cancer	0.00066	0.00113	CcSEcCtD
Cinacalcet—Arrhythmia—Epirubicin—ovarian cancer	0.000655	0.00112	CcSEcCtD
Cinacalcet—Asthenia—Paclitaxel—ovarian cancer	0.000654	0.00111	CcSEcCtD
Cinacalcet—Pruritus—Paclitaxel—ovarian cancer	0.000645	0.0011	CcSEcCtD
Cinacalcet—Malnutrition—Epirubicin—ovarian cancer	0.000638	0.00109	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000631	0.00108	CcSEcCtD
Cinacalcet—Diarrhoea—Paclitaxel—ovarian cancer	0.000623	0.00106	CcSEcCtD
Cinacalcet—Muscle spasms—Epirubicin—ovarian cancer	0.000614	0.00105	CcSEcCtD
Cinacalcet—Immune system disorder—Doxorubicin—ovarian cancer	0.000613	0.00104	CcSEcCtD
Cinacalcet—Body temperature increased—Docetaxel—ovarian cancer	0.00061	0.00104	CcSEcCtD
Cinacalcet—Abdominal pain—Docetaxel—ovarian cancer	0.00061	0.00104	CcSEcCtD
Cinacalcet—Arrhythmia—Doxorubicin—ovarian cancer	0.000606	0.00103	CcSEcCtD
Cinacalcet—Dizziness—Paclitaxel—ovarian cancer	0.000602	0.00103	CcSEcCtD
Cinacalcet—Malnutrition—Doxorubicin—ovarian cancer	0.000591	0.00101	CcSEcCtD
Cinacalcet—Anaemia—Epirubicin—ovarian cancer	0.00059	0.00101	CcSEcCtD
Cinacalcet—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	0.000584	0.0174	CbGpPWpGaD
Cinacalcet—Vomiting—Paclitaxel—ovarian cancer	0.000579	0.000987	CcSEcCtD
Cinacalcet—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	0.000579	0.0172	CbGpPWpGaD
Cinacalcet—Rash—Paclitaxel—ovarian cancer	0.000574	0.000979	CcSEcCtD
Cinacalcet—Dermatitis—Paclitaxel—ovarian cancer	0.000574	0.000978	CcSEcCtD
Cinacalcet—Headache—Paclitaxel—ovarian cancer	0.000571	0.000973	CcSEcCtD
Cinacalcet—Hypersensitivity—Docetaxel—ovarian cancer	0.000569	0.00097	CcSEcCtD
Cinacalcet—Muscle spasms—Doxorubicin—ovarian cancer	0.000568	0.000968	CcSEcCtD
Cinacalcet—CYP1A2—Estrogen Receptor Pathway—CYP1B1—ovarian cancer	0.000559	0.0166	CbGpPWpGaD
Cinacalcet—Cough—Epirubicin—ovarian cancer	0.000557	0.000949	CcSEcCtD
Cinacalcet—Asthenia—Docetaxel—ovarian cancer	0.000554	0.000944	CcSEcCtD
Cinacalcet—Convulsion—Epirubicin—ovarian cancer	0.000553	0.000943	CcSEcCtD
Cinacalcet—Hypertension—Epirubicin—ovarian cancer	0.000551	0.000939	CcSEcCtD
Cinacalcet—Pruritus—Docetaxel—ovarian cancer	0.000546	0.000931	CcSEcCtD
Cinacalcet—Anaemia—Doxorubicin—ovarian cancer	0.000546	0.00093	CcSEcCtD
Cinacalcet—Chest pain—Epirubicin—ovarian cancer	0.000543	0.000926	CcSEcCtD
Cinacalcet—Myalgia—Epirubicin—ovarian cancer	0.000543	0.000926	CcSEcCtD
Cinacalcet—Arthralgia—Epirubicin—ovarian cancer	0.000543	0.000926	CcSEcCtD
Cinacalcet—Nausea—Paclitaxel—ovarian cancer	0.000541	0.000922	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00054	0.00092	CcSEcCtD
Cinacalcet—Diarrhoea—Docetaxel—ovarian cancer	0.000528	0.000901	CcSEcCtD
Cinacalcet—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.000524	0.0156	CbGpPWpGaD
Cinacalcet—Infection—Epirubicin—ovarian cancer	0.000517	0.000882	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—HSD17B6—ovarian cancer	0.000517	0.0154	CbGpPWpGaD
Cinacalcet—Cough—Doxorubicin—ovarian cancer	0.000515	0.000878	CcSEcCtD
Cinacalcet—Convulsion—Doxorubicin—ovarian cancer	0.000512	0.000872	CcSEcCtD
Cinacalcet—Nervous system disorder—Epirubicin—ovarian cancer	0.000511	0.000871	CcSEcCtD
Cinacalcet—Dizziness—Docetaxel—ovarian cancer	0.000511	0.00087	CcSEcCtD
Cinacalcet—Hypertension—Doxorubicin—ovarian cancer	0.00051	0.000869	CcSEcCtD
Cinacalcet—Skin disorder—Epirubicin—ovarian cancer	0.000506	0.000862	CcSEcCtD
Cinacalcet—Chest pain—Doxorubicin—ovarian cancer	0.000503	0.000857	CcSEcCtD
Cinacalcet—Myalgia—Doxorubicin—ovarian cancer	0.000503	0.000857	CcSEcCtD
Cinacalcet—Arthralgia—Doxorubicin—ovarian cancer	0.000503	0.000857	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000499	0.000851	CcSEcCtD
Cinacalcet—Anorexia—Epirubicin—ovarian cancer	0.000497	0.000846	CcSEcCtD
Cinacalcet—Vomiting—Docetaxel—ovarian cancer	0.000491	0.000837	CcSEcCtD
Cinacalcet—Rash—Docetaxel—ovarian cancer	0.000487	0.00083	CcSEcCtD
Cinacalcet—Hypotension—Epirubicin—ovarian cancer	0.000487	0.00083	CcSEcCtD
Cinacalcet—Dermatitis—Docetaxel—ovarian cancer	0.000486	0.000829	CcSEcCtD
Cinacalcet—Headache—Docetaxel—ovarian cancer	0.000484	0.000825	CcSEcCtD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.00048	0.0143	CbGpPWpGaD
Cinacalcet—Infection—Doxorubicin—ovarian cancer	0.000479	0.000816	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000475	0.000809	CcSEcCtD
Cinacalcet—Nervous system disorder—Doxorubicin—ovarian cancer	0.000473	0.000806	CcSEcCtD
Cinacalcet—Skin disorder—Doxorubicin—ovarian cancer	0.000468	0.000798	CcSEcCtD
Cinacalcet—Paraesthesia—Epirubicin—ovarian cancer	0.000468	0.000797	CcSEcCtD
Cinacalcet—Dyspnoea—Epirubicin—ovarian cancer	0.000464	0.000792	CcSEcCtD
Cinacalcet—Anorexia—Doxorubicin—ovarian cancer	0.000459	0.000783	CcSEcCtD
Cinacalcet—Nausea—Docetaxel—ovarian cancer	0.000459	0.000782	CcSEcCtD
Cinacalcet—Dyspepsia—Epirubicin—ovarian cancer	0.000459	0.000782	CcSEcCtD
Cinacalcet—Decreased appetite—Epirubicin—ovarian cancer	0.000453	0.000772	CcSEcCtD
Cinacalcet—Hypotension—Doxorubicin—ovarian cancer	0.00045	0.000768	CcSEcCtD
Cinacalcet—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00045	0.0134	CbGpPWpGaD
Cinacalcet—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00045	0.000767	CcSEcCtD
Cinacalcet—Fatigue—Epirubicin—ovarian cancer	0.000449	0.000765	CcSEcCtD
Cinacalcet—Constipation—Epirubicin—ovarian cancer	0.000445	0.000759	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—DLC1—ovarian cancer	0.00044	0.0131	CbGpPWpGaD
Cinacalcet—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000439	0.000748	CcSEcCtD
Cinacalcet—Paraesthesia—Doxorubicin—ovarian cancer	0.000433	0.000738	CcSEcCtD
Cinacalcet—CYP1A2—Estrogen metabolism—CYP1B1—ovarian cancer	0.000431	0.0128	CbGpPWpGaD
Cinacalcet—Dyspnoea—Doxorubicin—ovarian cancer	0.00043	0.000732	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000426	0.000726	CcSEcCtD
Cinacalcet—Dyspepsia—Doxorubicin—ovarian cancer	0.000424	0.000723	CcSEcCtD
Cinacalcet—Decreased appetite—Doxorubicin—ovarian cancer	0.000419	0.000714	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000416	0.000709	CcSEcCtD
Cinacalcet—Fatigue—Doxorubicin—ovarian cancer	0.000416	0.000708	CcSEcCtD
Cinacalcet—Urticaria—Epirubicin—ovarian cancer	0.000414	0.000705	CcSEcCtD
Cinacalcet—Constipation—Doxorubicin—ovarian cancer	0.000412	0.000703	CcSEcCtD
Cinacalcet—Body temperature increased—Epirubicin—ovarian cancer	0.000412	0.000702	CcSEcCtD
Cinacalcet—Abdominal pain—Epirubicin—ovarian cancer	0.000412	0.000702	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000394	0.000672	CcSEcCtD
Cinacalcet—Hypersensitivity—Epirubicin—ovarian cancer	0.000384	0.000654	CcSEcCtD
Cinacalcet—Urticaria—Doxorubicin—ovarian cancer	0.000383	0.000653	CcSEcCtD
Cinacalcet—CYP1A2—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000381	0.0113	CbGpPWpGaD
Cinacalcet—Abdominal pain—Doxorubicin—ovarian cancer	0.000381	0.000649	CcSEcCtD
Cinacalcet—Body temperature increased—Doxorubicin—ovarian cancer	0.000381	0.000649	CcSEcCtD
Cinacalcet—Asthenia—Epirubicin—ovarian cancer	0.000374	0.000637	CcSEcCtD
Cinacalcet—Pruritus—Epirubicin—ovarian cancer	0.000369	0.000628	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—BCL9—ovarian cancer	0.000359	0.0107	CbGpPWpGaD
Cinacalcet—Diarrhoea—Epirubicin—ovarian cancer	0.000356	0.000607	CcSEcCtD
Cinacalcet—Hypersensitivity—Doxorubicin—ovarian cancer	0.000355	0.000605	CcSEcCtD
Cinacalcet—CYP1A2—Estrogen Receptor Pathway—ESR1—ovarian cancer	0.000351	0.0104	CbGpPWpGaD
Cinacalcet—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000347	0.0103	CbGpPWpGaD
Cinacalcet—Asthenia—Doxorubicin—ovarian cancer	0.000346	0.000589	CcSEcCtD
Cinacalcet—Dizziness—Epirubicin—ovarian cancer	0.000344	0.000587	CcSEcCtD
Cinacalcet—Pruritus—Doxorubicin—ovarian cancer	0.000341	0.000581	CcSEcCtD
Cinacalcet—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.000333	0.00989	CbGpPWpGaD
Cinacalcet—Vomiting—Epirubicin—ovarian cancer	0.000331	0.000565	CcSEcCtD
Cinacalcet—Diarrhoea—Doxorubicin—ovarian cancer	0.00033	0.000562	CcSEcCtD
Cinacalcet—Rash—Epirubicin—ovarian cancer	0.000328	0.00056	CcSEcCtD
Cinacalcet—Dermatitis—Epirubicin—ovarian cancer	0.000328	0.000559	CcSEcCtD
Cinacalcet—Headache—Epirubicin—ovarian cancer	0.000326	0.000556	CcSEcCtD
Cinacalcet—Dizziness—Doxorubicin—ovarian cancer	0.000319	0.000543	CcSEcCtD
Cinacalcet—CASR—G alpha (i) signalling events—CXCL8—ovarian cancer	0.000316	0.00939	CbGpPWpGaD
Cinacalcet—Nausea—Epirubicin—ovarian cancer	0.000309	0.000527	CcSEcCtD
Cinacalcet—Vomiting—Doxorubicin—ovarian cancer	0.000306	0.000522	CcSEcCtD
Cinacalcet—Rash—Doxorubicin—ovarian cancer	0.000304	0.000518	CcSEcCtD
Cinacalcet—Dermatitis—Doxorubicin—ovarian cancer	0.000304	0.000518	CcSEcCtD
Cinacalcet—Headache—Doxorubicin—ovarian cancer	0.000302	0.000515	CcSEcCtD
Cinacalcet—CYP1A2—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000294	0.00875	CbGpPWpGaD
Cinacalcet—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000294	0.00874	CbGpPWpGaD
Cinacalcet—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.000287	0.00852	CbGpPWpGaD
Cinacalcet—Nausea—Doxorubicin—ovarian cancer	0.000286	0.000488	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—DOK1—ovarian cancer	0.000283	0.00843	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	0.000272	0.00809	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PPP1CC—ovarian cancer	0.000266	0.00792	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	0.000261	0.00775	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	0.000248	0.00737	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	0.000248	0.00737	CbGpPWpGaD
Cinacalcet—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	0.000241	0.00718	CbGpPWpGaD
Cinacalcet—CASR—G alpha (q) signalling events—PIK3CA—ovarian cancer	0.000241	0.00715	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	0.000234	0.00696	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	0.000215	0.0064	CbGpPWpGaD
Cinacalcet—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000213	0.00634	CbGpPWpGaD
Cinacalcet—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000203	0.00605	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000203	0.00605	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000203	0.00605	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—HDAC6—ovarian cancer	0.000202	0.006	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—PPP2R1A—ovarian cancer	0.000199	0.00592	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	0.000199	0.00592	CbGpPWpGaD
Cinacalcet—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.000197	0.00584	CbGpPWpGaD
Cinacalcet—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000194	0.00577	CbGpPWpGaD
Cinacalcet—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000192	0.0057	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—CXCL8—ovarian cancer	0.000191	0.00569	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	0.000191	0.00567	CbGpPWpGaD
Cinacalcet—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.00019	0.00566	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—YAP1—ovarian cancer	0.000179	0.00531	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—XIAP—ovarian cancer	0.000175	0.00521	CbGpPWpGaD
Cinacalcet—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000173	0.00514	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—SMARCA4—ovarian cancer	0.000171	0.00507	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—EREG—ovarian cancer	0.000167	0.00495	CbGpPWpGaD
Cinacalcet—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000165	0.0049	CbGpPWpGaD
Cinacalcet—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000165	0.00489	CbGpPWpGaD
Cinacalcet—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000162	0.00483	CbGpPWpGaD
Cinacalcet—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000157	0.00468	CbGpPWpGaD
Cinacalcet—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000157	0.00467	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PGR—ovarian cancer	0.000156	0.00464	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000147	0.00437	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PARP1—ovarian cancer	0.000145	0.00431	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—IL6ST—ovarian cancer	0.000139	0.00413	CbGpPWpGaD
Cinacalcet—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000133	0.00396	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—PIK3CG—ovarian cancer	0.000133	0.00396	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000129	0.00384	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000128	0.0038	CbGpPWpGaD
Cinacalcet—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000127	0.00377	CbGpPWpGaD
Cinacalcet—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000125	0.00372	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PPP2R1A—ovarian cancer	0.000118	0.0035	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—PIK3CD—ovarian cancer	0.000117	0.00348	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000113	0.00334	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—CXCL8—ovarian cancer	0.000108	0.00321	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—IL2—ovarian cancer	0.000103	0.00307	CbGpPWpGaD
Cinacalcet—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000103	0.00306	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—PIK3CB—ovarian cancer	0.000102	0.00304	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—CXCL8—ovarian cancer	9.82e-05	0.00292	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—IL2—ovarian cancer	9.38e-05	0.00279	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—TERT—ovarian cancer	9.35e-05	0.00278	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	8.69e-05	0.00258	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	8.69e-05	0.00258	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CAV1—ovarian cancer	8.65e-05	0.00257	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	8.5e-05	0.00253	CbGpPWpGaD
Cinacalcet—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	8.36e-05	0.00249	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—ESR1—ovarian cancer	8.33e-05	0.00248	CbGpPWpGaD
Cinacalcet—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	8.25e-05	0.00245	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL6ST—ovarian cancer	8.2e-05	0.00244	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PIK3CG—ovarian cancer	7.88e-05	0.00234	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—APC—ovarian cancer	7.88e-05	0.00234	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—NRAS—ovarian cancer	7.88e-05	0.00234	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—MAPK3—ovarian cancer	7.54e-05	0.00224	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	7.22e-05	0.00215	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—MAPK1—ovarian cancer	7.18e-05	0.00213	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—EGFR—ovarian cancer	7.18e-05	0.00213	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	7.14e-05	0.00212	CbGpPWpGaD
Cinacalcet—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	7.08e-05	0.00211	CbGpPWpGaD
Cinacalcet—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	6.99e-05	0.00208	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PIK3CD—ovarian cancer	6.92e-05	0.00206	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—PIK3CA—ovarian cancer	6.86e-05	0.00204	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—KRAS—ovarian cancer	6.78e-05	0.00202	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	6.65e-05	0.00198	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	6.5e-05	0.00193	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	6.5e-05	0.00193	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	6.5e-05	0.00193	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—PIK3CA—ovarian cancer	6.23e-05	0.00185	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	6.14e-05	0.00183	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—ERBB2—ovarian cancer	6.12e-05	0.00182	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MTOR—ovarian cancer	6.04e-05	0.00179	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PIK3CB—ovarian cancer	6.04e-05	0.00179	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CXCL8—ovarian cancer	5.8e-05	0.00172	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—HRAS—ovarian cancer	5.76e-05	0.00171	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CDKN1B—ovarian cancer	5.66e-05	0.00168	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—AKT1—ovarian cancer	5.6e-05	0.00167	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CASP3—ovarian cancer	5.55e-05	0.00165	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL2—ovarian cancer	5.54e-05	0.00165	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—IL6—ovarian cancer	5.52e-05	0.00164	CbGpPWpGaD
Cinacalcet—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	5.47e-05	0.00163	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.46e-05	0.00162	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CCND1—ovarian cancer	5.4e-05	0.00161	CbGpPWpGaD
Cinacalcet—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	5.39e-05	0.0016	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—CTNNB1—ovarian cancer	5.35e-05	0.00159	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MMP9—ovarian cancer	5.25e-05	0.00156	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	5.22e-05	0.00155	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PTEN—ovarian cancer	5.22e-05	0.00155	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—NME2—ovarian cancer	5.1e-05	0.00152	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—AKT1—ovarian cancer	5.09e-05	0.00151	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—VEGFA—ovarian cancer	4.71e-05	0.0014	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—STAT3—ovarian cancer	4.66e-05	0.00139	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—NRAS—ovarian cancer	4.65e-05	0.00138	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MAPK3—ovarian cancer	4.46e-05	0.00132	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MYC—ovarian cancer	4.33e-05	0.00129	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—NME2—ovarian cancer	4.32e-05	0.00128	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MAPK1—ovarian cancer	4.24e-05	0.00126	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—EGFR—ovarian cancer	4.24e-05	0.00126	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—KRAS—ovarian cancer	4e-05	0.00119	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—PIK3CA—ovarian cancer	3.68e-05	0.00109	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.66e-05	0.00109	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—TP53—ovarian cancer	3.56e-05	0.00106	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—HRAS—ovarian cancer	3.4e-05	0.00101	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—NME2—ovarian cancer	3.33e-05	0.000991	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—CYTB—ovarian cancer	3.29e-05	0.000977	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL6—ovarian cancer	3.26e-05	0.000969	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—AKT1—ovarian cancer	3.01e-05	0.000894	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.99e-05	0.000888	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.87e-05	0.000854	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.87e-05	0.000854	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—CYTB—ovarian cancer	2.78e-05	0.000827	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.72e-05	0.000809	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.43e-05	0.000723	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.43e-05	0.000723	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—CYTB—ovarian cancer	2.15e-05	0.000639	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—YAP1—ovarian cancer	1.93e-05	0.000573	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.88e-05	0.000558	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.88e-05	0.000558	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.77e-05	0.000527	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—YAP1—ovarian cancer	1.63e-05	0.000485	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.61e-05	0.00048	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—FASN—ovarian cancer	1.57e-05	0.000467	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.54e-05	0.000459	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.49e-05	0.000443	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.43e-05	0.000425	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.42e-05	0.000422	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—FASN—ovarian cancer	1.33e-05	0.000395	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.31e-05	0.000389	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.27e-05	0.000377	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.26e-05	0.000376	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—YAP1—ovarian cancer	1.26e-05	0.000374	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.24e-05	0.000368	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.21e-05	0.00036	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.18e-05	0.00035	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—TYMS—ovarian cancer	1.16e-05	0.000344	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.07e-05	0.000319	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.07e-05	0.000318	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—FASN—ovarian cancer	1.03e-05	0.000305	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.01e-05	0.0003	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—ABCB1—ovarian cancer	9.98e-06	0.000297	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—TYMS—ovarian cancer	9.8e-06	0.000291	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—SLC2A1—ovarian cancer	9.75e-06	0.00029	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—CYP1B1—ovarian cancer	9.35e-06	0.000278	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—CAV1—ovarian cancer	9.32e-06	0.000277	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PIK3CG—ovarian cancer	8.49e-06	0.000252	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	8.29e-06	0.000247	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—CAV1—ovarian cancer	7.9e-06	0.000235	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—ABCB1—ovarian cancer	7.7e-06	0.000229	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—TYMS—ovarian cancer	7.56e-06	0.000225	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.54e-06	0.000224	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PIK3CD—ovarian cancer	7.46e-06	0.000222	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PIK3CG—ovarian cancer	7.19e-06	0.000214	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PIK3CB—ovarian cancer	6.5e-06	0.000193	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PIK3CD—ovarian cancer	6.32e-06	0.000188	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—CAV1—ovarian cancer	6.09e-06	0.000181	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PTEN—ovarian cancer	5.62e-06	0.000167	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PIK3CG—ovarian cancer	5.55e-06	0.000165	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PIK3CB—ovarian cancer	5.51e-06	0.000164	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.88e-06	0.000145	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PTEN—ovarian cancer	4.76e-06	0.000142	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PIK3CB—ovarian cancer	4.25e-06	0.000126	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.97e-06	0.000118	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PTEN—ovarian cancer	3.67e-06	0.000109	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.36e-06	9.99e-05	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—AKT1—ovarian cancer	3.24e-06	9.63e-05	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—AKT1—ovarian cancer	2.74e-06	8.16e-05	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.59e-06	7.71e-05	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—AKT1—ovarian cancer	2.12e-06	6.3e-05	CbGpPWpGaD
